501
Participants
Start Date
April 19, 2021
Primary Completion Date
August 31, 2027
Study Completion Date
March 31, 2028
Atezolizumab
atezolizumab 1200mg and bevacizumab 15mg/kg
Surgery
hepatic resection with post-operative atezolizumab 1200mg and bevacizumab 15mg/kg
Zhongshan hospital, Fudan University, Shanghai
Beijing Cancer Hospital, Beijing
Cancer Hospital Chinese Academy of Medical Science, Beijing
Peking Union Medical College Hospital, Beijing
Peking Univerty People's Hospital, Beijing
Xiangya Hospital of Central South University, Changsha
West China Hospital of Sichuan University, Chengdu
Fujian Provincial Hospital, Fuzhou
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou
Sun Yat-sen University Cancer Center, Guangzhou
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Anhui Provincial Hospital, Hefei
The Second Affiliated Hospital Kunming Medical University, Kunming
The First Hospital of Lanzhou University, Lanzhou
Jiangsu Provine People Hospital, Nanjing
Guangxi Medical University Cancer Hospital, Nanning
The First Affiliated Hospital Of Guangxi Medical University, Nanning
Shanghai Jiao Tong University Ruijin Hospital, Shanghai
Tianjin Medical University Cancer Institute & Hospital, Tianjin
Tongji Hospital of Tongji Medical College of HUST, Wuhan
Henan Province People Hospital, Zhengzhou
Jia Fan
OTHER